Pfizer, Partner of Nona Biosciences, Presents Preclinical Data of First-in-Class TOP1 Inhibitor-Based Anti-MSLN ADC PF-08052666 at AACR 2025
Pfizer
Pharmaceutical R&D Developer
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Nona Biologics, a company dedicated to cutting-edge technology innovation and providing partners with services covering target validation and the discovery to preclinical development of next-generation biologics, from Idea to IND (I to I).TM) A full-service international innovative biotechnology company, today announced that its partner Pfizer presented the preclinical data of PF-08052666 (HBM9033; SGN-MesoC2), a first-in-class antibody-drug conjugate (ADC) targeting human mesothelin (MSLN) based on a topoisomerase 1 inhibitor (TOP1i), at the 2025 American Association for Cancer Research (AACR) Annual Meeting.The ADC molecule isBased on Harbour Mice proprietary to Nanoray Biopharma®Developed by the antibody technology platform and integrated ADC technology platform。December 14, 2023Pfizer has obtained its global clinical development and commercialization rights.。
The information of the poster presented at the 2025 AACR Annual Meeting is as follows:
Title:PF-08052666 (HBM9033), a first-in-class topoisomerase 1 inhibitor-based ADC targeting MSLN, demonstrates potent antitumor activity in preclinical models of ovarian, lung, and colorectal cancers
PF-08052666 (HBM9033), a first-in-class, topoisomerase 1 inhibitor-based targeted mesothelin ADC therapy, demonstrated potent anti-tumor activity in preclinical models of ovarian cancer, lung cancer, and colorectal cancer.
Abstract Number:324
Poster Number:16
Report Session:Antireceptors and Other Biological Therapeutic Agents
Report Date:April 27, 2025
PF-08052666 adopts in its molecular designNovel antibodies, differentiated linker-payloads, and higher drug-to-antibody ratio (DAR), aiming to address the limitations of previous MSLN-targeted ADC therapies. This ADC consists of a fully human IgG1 monoclonal antibody linked to a potent TOP1i payload based on camptothecin through a protease-cleavable linker, with a DAR value averaging 8.
The main preclinical study results published this time include:
In vitro studies have shown that PF-08052666 directly exerts cytotoxic effects by delivering payloads to MSLN-positive cells and demonstrates killing activity against co-cultured MSLN-negative cells through a bystander effect.Even at physiological concentrations, soluble MSLNExistenceTheUnder the circumstances，PF-08052666 still possesses cell-killing capability.
In vivo study data show that PF-08052666 outperformed the DM4-based anti-MSLN benchmark ADC across various tumor cell lines and patient-derived xenograft models, including ovarian cancer, lung cancer, and colorectal cancer.
In a heterologous xenograft model composed of a mixture of MSLN-positive and MSLN-negative cells, PF-08052666 also demonstrated superior efficacy compared to the DM4-based anti-MSLN benchmark ADC, indicating that the novel linker-payload of MesoC2 has a more significant bystander effect.
The highly promising preclinical study results provided strong support for the initiation of the first-in-human Phase I clinical trial of PF-08052666 in patients with advanced solid tumors.Currently, the trial (NCT06466187) is undergoing participant recruitment.
Dr. Wang Jinsong, Chairman of Nanoray BiopharmaRepresentation:
The preclinical data of PF-08052666 disclosed by Pfizer at the 2025 AACR Annual Meeting fully demonstrates the strong capabilities of Nanoray Biotech’s platform and our firm commitment to advancing transformative therapies. With an industry-leading technology platform, Nanoray Biotech will continue to drive industry innovation and accelerate the development of next-generation biotherapies. We look forward to further deepening our collaboration with Pfizer to jointly expedite groundbreaking R&D progress in key areas, addressing urgent and unmet medical needs.
About PF-08052666 (HBM9033)
PF-08052666 is an antibody-drug conjugate (ADC) that specifically targets human mesothelin (MSLN), a tumor-associated antigen that is upregulated in various solid tumors. The fully human monoclonal antibody in PF-08052666 is derived from Harbour Mice.®The platform has excellent properties, maintaining strong binding and internalization with membrane-bound MSLN while reducing binding to soluble MSLN. The unique antibody design demonstrates outstanding efficacy in various preclinical tumor models with different MSLN expression levels, making PF-08052666 a potential best-in-class global therapy.
About Nanoray Biopharma
Nona Biotech is an international innovative biotechnology company. As a wholly-owned subsidiary of Harbour BioMed, it is committed to cutting-edge technology innovation and provides partners with end-to-end services ranging from target validation to preclinical development of diversified drug modalities.TM(Idea to IND) Full Service. By utilizing an integrated innovative technology platform and a globally leading team of scientists, the company provides a complete antibody discovery solution covering antigen preparation, animal immunization, single B-cell screening, antibody development and engineering, developability assessment, and pharmacological evaluation.
Harbour Mice®Fully human monoclonal antibodies in classic (H2L2) and heavy-chain only (HCAb) formats can be generated, working in tandem with a single B-cell cloning platform to optimize antibody discovery efficiency. Nona Biologics focuses on its proprietary technology platforms with global patents, empowering innovation at the source of China's biopharmaceutical industry and advancing the development of next-generation antibody therapeutics worldwide.
Copyright © 2025 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message to the WeChat Official Account backend or send a message, and indicate the name and ID of the official account.